Skip to main content
Oncotarget logoLink to Oncotarget
. 2018 Sep 25;9(75):34190. doi: 10.18632/oncotarget.26197

Correction: Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation

Inik Chang 1,*, Yozo Mitsui 2,3,*, Seul Ki Kim 1,4, Ji Su Sun 1,4, Hye Sook Jeon 1, Jung Yun Kang 1,4, Nam Ju Kang 1,4, Shinichiro Fukuhara 2,3, Ankurpreet Gill 2, Varahram Shahryari 2, Z Laura Tabatabai 5, Kirsten L Greene 5, Rajvir Dahiya 2,3, Dong Min Shin 1,4, Yuichiro Tanaka 2,3
PMCID: PMC6183339  PMID: 30344932

This article has been corrected: The image for #4-3 in Figure 2C is incorrect. It is a duplicate image of panel #4-2. The corrected Figure 2C is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Figure 2. CYP1B1 inhibition suppresses in vitro tumorigenicity.

Figure 2

(A and B) Expression of CYP1B1 mRNA (A) and protein (B) in CYP1B1 shRNA or control shRNA expressing PC-3 cells. Levels were determined by qRT-PCR and Western blot, respectively. (CH) Effect of CYP1B1 knockdown on in vitro tumorigenicity. Cell proliferation as determined by MTS assay at the indicated times. Representative images of cell morphology (left panel) and quantification of cell proliferation (right panel) are shown (C). Colony formation as determined by crystal violet staining. Representative image of colonies (left panel) and quantification of stained colonies (right panel) are shown (D). Apoptotic cell death as determined by flow cytometric analysis using double staining with Annexin V-FITC and 7-AAD. Representative biparametric histograms exhibiting cell (left panel) and quantification of apoptotic cells (right panel) are shown (E). Cell cycle progression as determined by DAPI staining (F). Cell migration (G) and invasion (H) capability as determined by transwell migration and invasion assay, respectively. Representative images (left panel) and quantification of assay (right panel) are shown. **p<0.01; ***p<0.001.

Original article: Oncotarget. 2017; 8:39087-39100. https://doi.org/10.18632/oncotarget.16598


Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES